期刊
TUMORI
卷 103, 期 2, 页码 101-113出版社
WICHTIG PUBLISHING
DOI: 10.5301/tj.5000608
关键词
ABVD; Brentuximab vedotin; Checkpoint inhibitors; Histology; Hodgkin lymphoma; Molecular biology
类别
资金
- AIRC 5 x 1000 [10007]
This article reviews the evolution of the diagnosis and treatment of Hodgkin lymphoma (HL) since its discovery in 1832. The morphological, phenotypic and molecular characteristics of both nodular lymphocyte-predominant HL and classical HL are revised in the light of recent molecular information and possible impact on the identification of risk groups as well as the use of targeted therapies. The seminal contribution of Gianni Bonadonna to developing new treatment strategies for both advanced and early-stage HL is highlighted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据